Artelo BiosciencesARTL +5.88%31 Debt-to-Equity is 0.11 as of Mar. 2026. GuruFocus rates ARTL with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 965 Biotechnology companies, Artelo Biosciences ranks better than 58.13% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Artelo Biosciences's Debt-to-Equity or its related term are showing as below:
ARTL'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1.58 Med: 0 Max: 0.15
Current: 0.11
During the past 12 years, the highest Debt-to-Equity Ratio of Artelo Biosciences was 0.15. The lowest was -1.58. And the median was 0.00.
ARTL's Debt-to-Equity is ranked better than 58.13% of 965
companies
in the Biotechnology industry
Industry Median: 0.16
vs ARTL: 0.11
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Artelo Biosciences Debt-to-Equity Related Terms
Artelo Biosciences Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Artelo Biosciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARTL vs REVB, MTNB, ONCO: Debt-to-Equity Comparison
For the Biotechnology subindustry, Artelo Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Artelo Biosciences Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Artelo Biosciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Artelo Biosciences's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Artelo Biosciences (ARTL) has a Debt-to-Equity of 0.11 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Artelo Biosciences and its competitors. According to the industry distribution chart, Artelo Biosciences ranks #404 out of 965 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Artelo Biosciences' Debt-to-Equity too high?
Artelo Biosciences' current Debt-to-Equity is 0.11. The Biotechnology industry median Debt-to-Equity is 0.16. Artelo Biosciences' value of 0.11 is 31.3% below this industry median. Based on the distribution chart, Artelo Biosciences ranks #404 out of 965 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Artelo Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Artelo Biosciences' Debt-to-Equity compare to REVB and MTNB?
According to the Biotechnology industry distribution chart, Artelo Biosciences ranks #404 out of 965 companies for Debt-to-Equity. This puts Artelo Biosciences in the upper half of its industry. The industry median Debt-to-Equity is 0.16. Artelo Biosciences' value of 0.11 is 31.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Artelo Biosciences's current Debt-to-Equity of 0.11 is 31.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Artelo Biosciences and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Artelo Biosciences's current Debt-to-Equity is 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artelo Biosciences stock overvalued right now?
Artelo Biosciences (ARTL) has a current Debt-to-Equity of 0.11. The current Debt-to-Equity is 0.11 and 31.3% below the Biotechnology industry median of 0.16. Artelo Biosciences' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Artelo Biosciences (ARTL), the current Debt-to-Equity is 0.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
31GF Score
Get the complete analysis for ARTL
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARTL has been successfully added to your 
